Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas
Blood (2019) 134 (Supplement_1): 241.
Currently there are no citedby results. Try again later.
